Submission completed, Spark sets sight on first ever US gene therapy approval – pharmaphorum
pharmaphorum |
Submission completed, Spark sets sight on first ever US gene therapy approval
pharmaphorum Spark Therapeutics has completed the rolling submission of gene therapy product voretigene neparvovec, for patients with a rare genetic form of blindness. The treatment offers a one-time gene therapy for patients with vision loss due to confirmed … Spark Therapeutics (ONCE) Completes Rolling BLA Submission to FDA for Investigational Gene Therapy Voretigene … |
